Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics announced positive results from Phase 1b studies on rezpegaldesleukin for atopic dermatitis and psoriasis, showing durable improvements in disease activity and patient outcomes.
October 29, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nektar Therapeutics' Phase 1b studies show promising results for rezpegaldesleukin in treating atopic dermatitis and psoriasis, indicating potential positive impact on stock price.
The positive results from the Phase 1b studies suggest that rezpegaldesleukin is effective in treating inflammatory skin conditions, which could lead to increased investor confidence and a potential rise in NKTR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100